Prognostic Gene Signatures in Bladder Cancer Treatment
Author Information
Author(s): Cho Mina, Chang Hyun, Kim Ju Han
Primary Institution: Seoul National University College of Medicine
Hypothesis
This study aims to identify reliable biomarkers to enhance the prediction of treatment outcomes in bladder cancer patients treated with immune checkpoint inhibitors.
Conclusion
The study demonstrated that the bladder cancer gene signature (BC-GS) can effectively predict survival outcomes in patients treated with immune checkpoint inhibitors.
Supporting Evidence
- Patients with low BC-GS had a significantly shorter overall survival than those with high BC-GS.
- Genes in the BC-GS were involved in CD8+ T cell activation and immune checkpoint pathways.
- The combined assessment of BC-GS and tumor mutation burden may enhance patient stratification.
Takeaway
Researchers found a way to tell which bladder cancer patients might do better with a specific treatment by looking at certain genes.
Methodology
The study integrated bulk RNA-seq and single-cell RNA-seq data to identify differentially expressed genes associated with survival outcomes.
Potential Biases
The study may have biases due to the retrospective nature and harmonization challenges across datasets.
Limitations
The retrospective design and the use of simple median cutoffs may lack precision, and further validation in prospective studies is needed.
Participant Demographics
The study analyzed data from 89 bladder cancer patients and 7 patients with single-cell RNA-seq data.
Statistical Information
P-Value
p=0.008 in GSE176307; p=0.043 in IMvigor210; p=0.00081 in UC-GENOME
Confidence Interval
95% CI=0.29–0.84
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website